Single Sample. Superior Sensitivity. Deeper Insights.
Bio-Techne’s multiomics platform provides a comprehensive view of disease by combining genomic data with data from other modalities, including transcriptomics, epigenomics, and proteomics. This approach enables a multifaceted understanding of the molecular changes contributing to disease, allowing researchers to connect genotypes to phenotypes and discover novel drug targets and biomarkers.
| Supported Sample Types | Integrated Multiomics | BioInformatics & Machine Learning |
|---|---|---|
|
Comprehensive analysis combining:
The platform harnesses the unique power of exosomal RNA and protein analysis combined with genomics and epigenomics of cell-free DNA for improved sensitivity and earlier diagnosis |
Our integrative analytics aim to provide |
Bio-Techne's Multiomics Platform Workflow
The liquid biopsy platform analyzes gene expression, splice variants, gene fusions, mutations, DNA methylation, and proteins. This platform integrates bioinformatics and machine learning for discovery of multi-analyte biomarker signatures, allowing a multifaceted view of a patient’s disease.
Multiomics for Precision Medicine
Complex diseases, such as cancer, auto-immune disorders, and neurodegenerative diseases, create characteristic signatures in DNA, RNA, proteins, and metabolites. Multiomics technologies aim to systematically identify these signatures at different biological levels. Advances in multiomics technologies and the convenience of obtaining multiomics data are accelerating predictive, preventive, and personalized medicine practices, allowing for improved patient stratification and personalization of medicine.
Additional Resources
Bio-Techne is a one-stop-shop for biomarker discovery, fit-for-purpose assay development and validation, with commercialization of CDx products, enabling pharma partners to accelerate their pharmaceutical clinical trials.
Case Study: Multiomics Analysis Using Bio-Techne’s Platform for Enhanced CRC Classification
A pilot study in colorectal cancer (CRC) screening using the Bio-Techne platform shows the value of integrating multiomic readouts for enhanced CRC classification. The underlying platform can be applied to biomarker signature development and is designed for extension to downstream assay development for clinical trial applications.
Genomic Profiling, Advantages of Liquid Biopsy-Based Biomarkers
This application note addresses a variety of experimental approaches related to exosome isolation and genomic profiling. Some elements covered include:
- Accurately characterize and stratify patient populations
- Versatility in target analytes
- Analyze non-invasive biofluids
- Create customized experimental approaches